<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595879</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-01907</org_study_id>
    <secondary_id>NCI-2015-01907</secondary_id>
    <secondary_id>UPCI 15-157</secondary_id>
    <secondary_id>15-157</secondary_id>
    <secondary_id>9892</secondary_id>
    <secondary_id>9892</secondary_id>
    <secondary_id>UM1CA186690</secondary_id>
    <nct_id>NCT02595879</nct_id>
  </id_info>
  <brief_title>Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer</brief_title>
  <official_title>Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of triapine when given with&#xD;
      radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal&#xD;
      cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell&#xD;
      growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their&#xD;
      deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard&#xD;
      treatment with cisplatin and radiation therapy may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral&#xD;
      triapine when used in combination with cisplatin plus radiation therapy.&#xD;
&#xD;
      II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics&#xD;
      (PK) of oral and intravenous triapine.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether the metabolic complete response (mCR) rate of oral triapine in&#xD;
      combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron&#xD;
      emission tomography (PET) computed tomography (CT) at post-therapy (3-month) is at least 70%.&#xD;
&#xD;
      II. To determine clinical overall response rate, progression-free survival, and overall&#xD;
      survival.&#xD;
&#xD;
      III. To determine the correlation of methemoglobin proportion (%) and triapine&#xD;
      pharmacokinetic exposure.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy&#xD;
      impacts the antitumor activity of triapine.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of triapine.&#xD;
&#xD;
      Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated&#xD;
      radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in&#xD;
      week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions&#xD;
      of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine&#xD;
      intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26,&#xD;
      and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes&#xD;
      once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin&#xD;
      IV during the parametrial boost or any make-up radiation treatment in a sixth week of&#xD;
      external beam radiotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT) to determine maximum tolerated dose</measure>
    <time_frame>5 weeks</time_frame>
    <description>MTD is defined as the dose level where &lt; 2/6 DLTs are observed. DLT will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (version 5.0 beginning April 1, 2018).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral bioavailability of the oral form of the triapine</measure>
    <time_frame>Days 1 and 11</time_frame>
    <description>The oral bioavailability of the oral form of the triapine will be estimated with corresponding 95% CI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Toxicity will be evaluated using the NCI CTCAE version 4.0 (version 5.0 beginning April 1, 2018). The rate of DLT at maximum tolerated dose will be calculated and the exact 95% confidence intervals (CI) will be provided. The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category and grade. All DLTs and other serious (&gt;= grade 3) events will be described on a patient-by-patient basis; descriptions will include dose level and any relevant baseline data. Statistics on the number of cycles received by patients and any dose reductions will also be tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fludeoxyglucose F 18 (18F-FDG)-Positron emission tomography (PET) computed tomography (CT) metabolic complete response (mCR) rate</measure>
    <time_frame>3 months post-treatment</time_frame>
    <description>The mCR rate at recommended phase 2 dose will be calculated with corresponding 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical overall response</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>The overall response rate at recommended phase II dose (RP2D) will be calculated with corresponding 95% exact CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Will be analyzed using the Kaplan-Meier's method. Median survival time will be reported with corresponding 95% CIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Will be analyzed using the Kaplan-Meier's method. Median survival time will be reported with corresponding 95% CIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters</measure>
    <time_frame>Baseline (prior to infusion); 30, 60, 90, 110, 2 hours 30 minutes, and 3 hours after the start of the infusion</time_frame>
    <description>Standard PK parameters will be determined and will include maximum concentration, time to maximum concentration, drug clearance, steady state concentration, and half-life. These parameters will be descriptively reported. The association of methemoglobin proportion (%) and PK parameters will be evaluated by Spearman correlation coefficients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Advanced Cervical Adenocarcinoma</condition>
  <condition>Advanced Cervical Adenosquamous Carcinoma</condition>
  <condition>Advanced Cervical Squamous Cell Carcinoma</condition>
  <condition>Advanced Vaginal Adenocarcinoma</condition>
  <condition>Stage IB2 Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage II Cervical Cancer AJCC v7</condition>
  <condition>Stage II Vaginal Cancer AJCC v6 and v7</condition>
  <condition>Stage IIA1 Cervical Cancer AJCC v7</condition>
  <condition>Stage IIA2 Cervical Cancer AJCC v7</condition>
  <condition>Stage IIB Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage III Vaginal Cancer AJCC v6 and v7</condition>
  <condition>Stage IIIB Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage IVA Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage IVA Vaginal Cancer AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Undergo LDR brachytherapy</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <other_name>Brachytherapy, NOS</other_name>
    <other_name>Internal Radiation</other_name>
    <other_name>Internal Radiation Brachytherapy</other_name>
    <other_name>Internal Radiation Therapy</other_name>
    <other_name>Radiation Brachytherapy</other_name>
    <other_name>Radiation, Internal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo pelvic EBRT</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiation</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
    <other_name>Radiation, External Beam</other_name>
    <other_name>Teleradiotherapy</other_name>
    <other_name>Teletherapy</other_name>
    <other_name>Teletherapy Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High-Dose Rate Brachytherapy</intervention_name>
    <description>Undergo HDR brachytherapy</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <other_name>Brachytherapy, High Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
    <other_name>Radiation, Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triapine</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (triapine, chemoradiation)</arm_group_label>
    <other_name>3-aminopyridine-2-carboxaldehyde thiosemicarbazone</other_name>
    <other_name>3-AP</other_name>
    <other_name>3-Apct</other_name>
    <other_name>OCX-0191</other_name>
    <other_name>OCX-191</other_name>
    <other_name>OCX191</other_name>
    <other_name>PAN-811</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has a new, untreated histologic diagnosis of stage IB2 (&gt; 5 cm), II, IIIB,IIIC&#xD;
             or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or&#xD;
             stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not&#xD;
             amenable to curative surgical resection alone; the presence or absence of para-aortic&#xD;
             lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be&#xD;
             able to tolerate imaging requirements of an 18F-FDG PET/CT scan&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy greater than 6 months&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 10.0 g/dL (blood transfusions to reach this amount are allowed)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL to receive weekly cisplatin&#xD;
&#xD;
               -  If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for&#xD;
                  cisplatin if the estimated creatinine clearance (CCr) is &gt; 30 ml/min (for the&#xD;
                  purpose of estimating the CCr, the formula of Cockcroft and Gault for females&#xD;
                  should be used)&#xD;
&#xD;
          -  Total serum bilirubin =&lt; 1.5 x upper limit of normal (ULN) (in patients with known&#xD;
             Gilbert syndrome, a total bilirubin =&lt; 3.0 x ULN, with direct bilirubin =&lt; 1.5 x ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Not pregnant and not breastfeeding; the effects of triapine on the developing human&#xD;
             fetus are unknown; for this reason as well as because heterocyclic&#xD;
             carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of&#xD;
             child-bearing potential and men must agree to use two forms of contraception (hormonal&#xD;
             or barrier method of birth control; abstinence) prior to study entry and for the&#xD;
             duration of study participation; patient must have documented negative urine pregnancy&#xD;
             test must be resulted within 7 days before initiating protocol therapy; should a woman&#xD;
             become pregnant or suspect she is pregnant while participating in this study, she&#xD;
             should inform her treating physician immediately; because there is an unknown but&#xD;
             potential risk for adverse events in nursing infants secondary to treatment of the&#xD;
             mother with triapine, breastfeeding should be discontinued if the mother is treated&#xD;
             with triapine; these potential risks may also apply to other agents used in this study&#xD;
&#xD;
          -  For human immunodeficiency virus (HIV) and hepatitis B/C (HEPB/C):&#xD;
&#xD;
               -  HIV-infected patients on effective anti-retroviral therapy with undetectable&#xD;
                  viral load within 6 months are eligible for the dose escalation portion of this&#xD;
                  trial; for those patients who are enrolled in the HIV positive (+) expansion&#xD;
                  cohort, they must be HIV infected and be on retroviral therapy with an&#xD;
                  undetectable viral load within 6 months of enrollment&#xD;
&#xD;
               -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV&#xD;
                  viral load must be undetectable on suppressive therapy, if indicated&#xD;
&#xD;
               -  Patients with a history of hepatitis C virus (HCV) infection must have been&#xD;
                  treated and cured; for patients with HCV infection who are currently on&#xD;
                  treatment, they are eligible if they have an undetectable HCV viral load&#xD;
&#xD;
          -  Able to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has had a prior invasive malignancy diagnosed within the last three years&#xD;
             (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)&#xD;
&#xD;
          -  Patients are excluded if they have received prior pelvic radiotherapy for any reason&#xD;
             that would contribute radiation dose that would exceed tolerance of normal tissues at&#xD;
             the discretion of the treating physician&#xD;
&#xD;
          -  Patients receiving any other investigational agents&#xD;
&#xD;
          -  Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded&#xD;
             due to an inability to administer the antidote for methemoglobinemia, methylene blue;&#xD;
             pre-registration testing for G6PD is at the investigator's discretion and is not&#xD;
             required for study enrollment&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to triapine or cisplatin&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac&#xD;
             arrhythmia; known inadequately controlled hypertension; significant pulmonary disease&#xD;
             including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary&#xD;
             reserve; or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by&#xD;
             medication, =&lt; 200 mg/dL allowed)&#xD;
&#xD;
          -  Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy&#xD;
             following radiation as part of their cervical cancer treatment are ineligible&#xD;
&#xD;
          -  Patients scheduled to be treated with adjuvant consolidation chemotherapy at the&#xD;
             conclusion of their standard chemoradiation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah E Taylor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Cancer Institute LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center of USC Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Indian Creek Campus</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Mark E. Bernard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ira S. Winer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ira S. Winer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-235-7356</phone>
    </contact>
    <investigator>
      <last_name>Eugenia Girda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Debra L. Richardson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-647-8073</phone>
    </contact>
    <investigator>
      <last_name>Sarah E. Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

